Robert Justice

Author PubWeight™ 1.10^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.	Oncologist	2014	1.14